Protein splice renders statins inefffective for some

One more tiny step in the long march toward personalized drug treatment: Researchers found a protein quirk that makes statins less than effective in some people. The protein, called UMGCR, plays a role in producing LDL, or "bad" cholesterol. Some people use HMGCR to produce LDL in a different way, and that difference can interfere with the statin effect. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.